![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Tinel, V Descatoire, D Larrey, J Loeper, G Labbe, P Letteron and D Pessayre
Unite de Recherches de Physiopathologie Hepatique (Institut National de la Sante et de la Recherche Medicale U 24), Hopital, Beaujon, Clichy, France.
Repeated administration of clarithromycin (0.5 mmol.kg-1 p.o. daily for 5 days) to rats increased markedly the same cytochrome P-450 isoenzyme (P-450p) as that induced by troleandomycin. Clarithromycin, however, did not form cytochrome P-450 Fe(II)-metabolite complexes in vitro with microsomes from clarithromycin-treated rats or in vivo after repeated doses of clarithromycin. Nevertheless, clarithromycin formed cytochrome P-450 Fe(II)-metabolite complexes with microsomes from dexamethasone- treated rats in vitro, or after administration to dexamethasone-treated rats in vivo. Similar effects were observed with roxithromycin. In contrast, erythromycin and troleandomycin formed metabolic complexes when given alone, whereas josamycin, midecamycin and spiramycin did not form complexes, even in dexamethasone-treated rats. We conclude that clarithromycin and roxithromycin induce cytochrome P-450p, but do not form complexes with this isoenzyme, although they do form complexes with other glucocorticoid-inducible isoenzymes. We propose that macrolides may be classified into three groups, those forming complexes when given alone (e.g., erythromycin and troleandomycin), those forming complexes only in glucocorticoid-pretreated rats (clarithromycin and roxithromycin) and those not forming complexes (josamycin, midecamycin and spiramycin).
This article has been cited by other articles:
|
|
 |
|
  K. Ito, K. Ogihara, S.-i. Kanamitsu, and T. Itoh PREDICTION OF THE IN VIVO INTERACTION BETWEEN MIDAZOLAM AND MACROLIDES BASED ON IN VITRO STUDIES USING HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2003; 31(7): 945 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ledirac, G. de Sousa, F. Fontaine, C. Agouridas, J. Gugenheim, G. Lorenzon, and R. Rahmani Effects of Macrolide Antibiotics on CYP3A Expression in Human and Rat Hepatocytes: Interspecies Differences in Response to Troleandomycin Drug Metab. Dispos., April 13, 2001; 28(12): 1391 - 1393. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Mayhew, D. R. Jones, and S. D. Hall An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation Drug Metab. Dispos., September 1, 2000; 28(9): 1031 - 1037. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Yamano, K. Yamamoto, H. Kotaki, S. Takedomi, H. Matsuo, Y. Sawada, and T. Iga Quantitative Prediction of Metabolic Inhibition of Midazolam by Erythromycin, Diltiazem, and Verapamil in Rats: Implication of Concentrative Uptake of Inhibitors into Liver J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1118 - 1126. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki and T. Shimada Comparative Studies of In Vitro Inhibition of Cytochrome P450 3A4-Dependent Testosterone 6beta -Hydroxylation by Roxithromycin and Its Metabolites, Troleandomycin, and Erythromycin Drug Metab. Dispos., November 1, 1998; 26(11): 1053 - 1057. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Rodrigues, E. M. Roberts, D. J. Mulford, Y. Yao, and D. Ouellet Oxidative Metabolism of Clarithromycin in the Presence of Human Liver Microsomes. Major Role for the Cytochrome P4503A (CYP3A) Subfamily Drug Metab. Dispos., May 1, 1997; 25(5): 623 - 630. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
